Acquired Reactive Perforating Collagenosis Successfully Treated with Narrow-band Ultraviolet B: A Case Report
DOI:
https://doi.org/10.66344/jpad.v36i2.3189Keywords:
acquired perforating dermatoses, acquired reactive perforating collagenosis, phototherapy, NB-UVBAbstract
Acquired reactive perforating collagenosis (ARPC) is a form of dermatoses, that is characterized by transepidermal elimination of collagen fibers through the epidermis. Management of ARPC becomes a challenge due to the lack of an established standard treatment protocol. In patients who do not respond to conventional therapy, narrowband ultraviolet B (NB-UVB) has become an option. In our case report, a 51- year-old male patient presented with erythematous papules and nodules throughout his body with a history of chronic kidney disease, hepatitis B infection, diabetes mellitus, and hypertension. A diagnosis of ARPC through clinical examination, histopathology, and immunochemistry examination was confirmed. After one year course of therapy, including oral therapy (corticosteroid and antihistamine) and topical therapy (a combination of topical salicylic acid with corticosteroid), the patient still showed no improvement. After the administration of NB-UVB phototherapy (three times a week for two and a half months), the lesions were significantly improved. This case report highlights the efficacy of NB-UVB in ARPC that did not improve with traditional management.
References
Rapini RP, Herbert AA, Drucker CR. Acquired perforating dermatoses. Evidence for combined transepidermal elimination of both collagen and elastic fibers. Arch Dermatol. 1989;125(8):1074-1078. doi:10.1001/archderm.125.8.1074
Malkud S, Dyavannanavar V, Varala S. Cutaneous manifestations in patients with chronic kidney disease on hemodialysis. J Pak Assoc Dermatol [Internet]. 2020Oct.1 [cited 2025Apr.28];30(3):490-6. Available from: https://www.jpad.com.pk/index.php/jpad/article/view/1494
Pushpa M, Murthy SC, Anvar MI. Mucocutaneous manifestations and nail changes in patients with end stage renal disease: A cross-sectional study. J Pak Assoc Dermatol [Internet]. 2021Aug.6 [cited 2025Apr.28];31(2):191-200. Available from: https://www.jpad.com.pk/index.php/jpad/article/view/1763
Haseer Koya H, Ananthan D, Varghese D, Njeru M, Curtiss C, Khanna A. Acquired reactive perforating dermatosis: a rare skin manifestation in end stage renal disease. Nephrology (Carlton). 2014;19(8):515-516. doi:10.1111/nep.12289
Kawakami T, Akiyama M, Ishida-Yamamoto A, et al. Clinical practice guide for the treatment of perforating dermatoses. J Dermatol. 2020;47(12):1374-1382. doi:10.1111/1346-8138.15647
Faver IR, Daoud MS, Su WP. Acquired reactive perforating collagenosis. Report of six cases and review of the literature. J Am Acad Dermatol. 1994;30(4):575-580. doi:10.1016/s0190-9622(94)70065-6
Lynde CB, Pratt MD. Clinical Images: Acquired perforating dermatosis: association with diabetes and renal failure. CMAJ. 2009;181(9):615. doi:10.1503/cmaj.082013
Gambichler T, Altmeyer P, Kreuter A. Treatment of acquired perforating dermatosis with narrowband ultraviolet B. J Am Acad Dermatol. 2005;52(2):363-364. doi:10.1016/j.jaad.2004.08.018
Gao L, Gu L, Chen Z, Cao S. Doxycycline Combined with NB-UVB Phototherapy for Acquired Reactive Perforating Collagenosis. Ther Clinic Risk Manag. 2020;16:917-921. Published 2020 Sep 24. doi:10.2147/TCRM.S271058
Leino L, Saarinen K, Kivistö K, Koulu L, Jansen CT, Punnonen K. Systemic suppression of human peripheral blood phagocytic leukocytes after whole-body UVB irradiation. J Leukoc Biol. 1999;65(5):573-582. doi:10.1002/jlb.65.5.573
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Journal of Pakistan Association of Dermatologists
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
